MedPath

BAYER AG

BAYER AG logo
πŸ‡©πŸ‡ͺGermany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Phase 1
Completed
Conditions
Castration-Resistant Prostate Cancer
Bone Metastases
Interventions
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
Drug: Docetaxel
First Posted Date
2010-04-19
Last Posted Date
2017-01-04
Lead Sponsor
Bayer
Target Recruit Count
70
Registration Number
NCT01106352

Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice

Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Vardenafil (Levitra, BAY38-9456)
First Posted Date
2010-04-19
Last Posted Date
2016-10-17
Lead Sponsor
Bayer
Target Recruit Count
2289
Registration Number
NCT01106118

Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

Phase 1
Completed
Conditions
Anti-Infective Agents
Interventions
Drug: Cephalexin suspension (Optocef, BAYO5448 )
Drug: Cephalexin suspension (Keflex)
First Posted Date
2010-04-16
Last Posted Date
2014-05-20
Lead Sponsor
Bayer
Target Recruit Count
26
Registration Number
NCT01105208

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
First Posted Date
2010-04-15
Last Posted Date
2014-11-11
Lead Sponsor
Bayer
Target Recruit Count
460
Registration Number
NCT01104584

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Phase 3
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Placebo
Drug: Regorafenib (Stivarga, BAY73-4506)
Other: Best Supportive Care (BSC)
First Posted Date
2010-04-14
Last Posted Date
2015-06-24
Lead Sponsor
Bayer
Target Recruit Count
760
Registration Number
NCT01103323

Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients

First Posted Date
2010-04-05
Last Posted Date
2013-10-31
Lead Sponsor
Bayer
Target Recruit Count
151
Registration Number
NCT01098760

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Completed
Conditions
Secondary Peritonitis
Abscess, Intra-Abdominal
Interventions
Drug: Moxifloxacin (Avelox, BAY12-8039)
First Posted Date
2010-03-31
Last Posted Date
2013-06-21
Lead Sponsor
Bayer
Target Recruit Count
1001
Registration Number
NCT01096511

Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel

Phase 1
Completed
Conditions
Contraception
Contraception, Postcoital
Interventions
Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Drug: Levonorgestrel (Postday)
First Posted Date
2010-03-31
Last Posted Date
2013-06-11
Lead Sponsor
Bayer
Target Recruit Count
24
Registration Number
NCT01096485

Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel

Phase 1
Completed
Conditions
Contraception
Contraception, Postcoital
Interventions
Drug: Levonorgestrel (Postday)
Drug: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
First Posted Date
2010-03-31
Last Posted Date
2013-06-11
Lead Sponsor
Bayer
Target Recruit Count
24
Registration Number
NCT01096498

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: Regorafenib (Stivarga, BAY73-4506)
First Posted Date
2010-03-30
Last Posted Date
2013-11-19
Lead Sponsor
Bayer
Target Recruit Count
33
Registration Number
NCT01096030
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy